We’re excited to share that Biocytogen will be attending the 19th Annual European Life Sciences CEO Forum from March 4th - 5th in Opfikon, Switzerland. Join us in exploring the latest developments and strategies within the biopharma industry in 2026. Come network with top executives and key stakeholders from around the world. We look forward to discussing how Biocycogen’s innovative tools and services can help advance your research.
What is the 19th Annual European Life Sciences CEO Forum?
The 19th Annual European Life Sciences CEO Forum is a major summit drawing in 400+ delegates, including investors and pharma licensing experts, looking to network within the biotech industry. This year’s event will showcase up to 50 global public, private, emerging, and seed companies, offering new technologies and innovative ideas. WIth dedicated meeting rooms and a virtual meeting system, this is the perfect opportunity to form meaningful connections.
Event Overview
Date: March 4th - 5th, 2026
Venue: Hilton Zurich Airport, Hohenbühlstrasse 10, 8152 Opfikon, Switzerland
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to seeing you in Switzerland!
